Since the discovery of sickle cell disease (SCD) in 1910, enormous strides have been made
in the elucidation of the pathogenesis of its protean complications, which has inspired recent …

Phosphodiesterases (PDEs), enzymes that degrade 3′, 5′-cyclic nucleotides, are being
pursued as therapeutic targets for several diseases, including those affecting the nervous …

Sickle cell disease (SCD) is a severe genetic blood disorder characterized by hemolytic
anemia, episodic vaso-occlusion, and progressive organ damage. Current management of …

Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell
disease. Symptomatic management and prevention of these events using the fetal …

The primary β-globin gene mutation that causes sickle cell disease (SCD) has significant
pathophysiological consequences that result in hemolytic events and the induction of the …

For over 100 years, clinicians and scientists have been unravelling the consequences of the
A to T substitution in the β-globin gene that produces haemoglobin S, which leads to the …

Introduction: Sickle cell anemia (SCA) is a severe, inherited hemoglobin disorder affecting
100,000 persons in the US and millions worldwide. Hydroxyurea, a once daily oral …

Despite significant evidence implicating an important role for neutrophils in thrombosis, their
impact on the thrombotic process has remained a matter of controversy. Until 2010, platelets …

Abstract When Furchgott, Murad, and Ignarro were honored with the Nobel prize for the
identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could …

Cyclic guanosine monophosphate (cGMP) is a unique second messenger molecule formed
in different cell types and tissues. cGMP targets a variety of downstream effector molecules …